An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its first-quarter 2024 financial results on May 8, 2024. The company, focused on CNS diseases, will host a conference call with President and CEO Jack Khattar and CFO Tim Dec. The call will include a live webcast accessible on the Investor Relations website.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) annuncerà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024. La compagnia, specializzata in malattie del sistema nervoso centrale, organizzerà una conferenza telefonica con il Presidente e CEO Jack Khattar e il CFO Tim Dec. La chiamata includerà una trasmissione web in diretta accessibile sul sito web delle Relazioni con gli Investitori.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) anunciará los resultados financieros de su primer trimestre de 2024 el 8 de mayo de 2024. La empresa, enfocada en enfermedades del SNC, llevará a cabo una llamada de conferencia con el presidente y CEO Jack Khattar y el CFO Tim Dec. La llamada incluirá una transmisión en vivo accesible en el sitio web de Relaciones con Inversores.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN)는 2024년 5월 8일에 2024년 1분기 재무 결과를 발표할 예정입니다. 중추신경계 질환에 중점을 둔 이 회사는 회장 겸 CEO 잭 카타르와 CFO 팀 데크와 함께 컨퍼런스 콜을 주최할 것입니다. 이 콜은 투자자 관계 웹사이트에서 접근 가능한 라이브 웹캐스트를 포함할 예정입니다.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) annoncera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024. La société, centrée sur les maladies du SNC, organisera une conférence téléphonique avec le président et PDG Jack Khattar et le CFO Tim Dec. L'appel comprendra une webdiffusion en direct accessible sur le site web des Relations avec les Investisseurs.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) wird am 8. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen, das sich auf ZNS-Krankheiten spezialisiert hat, wird eine Telefonkonferenz mit dem Präsidenten und CEO Jack Khattar sowie CFO Tim Dec veranstalten. Das Gespräch umfasst einen live webcast, der auf der Website für Investor Relations zugänglich ist.
Positive
None.
Negative
None.
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2024 financial and business results on Wednesday, May 8, 2024 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Jack A. Khattar, President and CEO Timothy C. Dec, Senior Vice President and CFO Supernus Pharmaceuticals, Inc. (301) 838-2591
or
INVESTOR CONTACT: Peter Vozzo ICR Westwicke (443) 213-0505 peter.vozzo@westwicke.com
FAQ
When will Supernus Pharmaceuticals announce its first-quarter 2024 financial results?
Supernus Pharmaceuticals will announce its first-quarter 2024 financial results on May 8, 2024.
Who will host the conference call for Supernus Pharmaceuticals?
President and CEO Jack Khattar and CFO Tim Dec will host the conference call for Supernus Pharmaceuticals.
Where can participants access the live webcast of the conference call?
Participants can access the live webcast of the conference call in the Events & Presentations section of the Company's Investor Relations website at www.supernus.com/investors.
How long will the webcast be available on the Company's website after the live call?
The webcast will be available on the Company's website for 60 days following the live call.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
